enGene Q1 net loss $24.6M ($0.48/sh); cash $272.8M; LEGEND on track for BLA mid-2026

enGene Therapeutics Inc.

2025-Q1 EPS reported $0.48

Net loss $24.6M ($0.48 per share) for Q1 ended Jan 31, 2025, vs $10.7M ($0.46) a year ago.
Cash and marketable securities $272.8M; expected runway into 2027.
Total operating expenses $26.6M, up from $10.8M, driven by LEGEND study costs and headcount.
LEGEND pivotal cohort enrollment on track for BLA filing mid-2026; trial sites expanded to Europe/Asia.
Amended protocol adds maintenance dosing for patients in CR at 12 months up to 3 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.